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ABSTRACT
Hepatitis C is the most pressing public health challenge in Egypt where Hepatitis
C Virus (HCV) prevalence is the highest in the world. In 2015, Egypt Health Issues
Survey showed that 10% of Egyptians between 15 – 59 years of age had been infected
with HCV infection, while 7% are chronic active hepatitis C patients. This paper aims
to estimate the current and future economic and epidemiological burden of HCV
between 2015 and 2025. In addition, it compares the impact of different scenarios for
management of this huge public health problem to identify the most cost effective
strategy capable of reducing the economic and epidemiological burden of this disease
at the country level. A Markov model representing hepatitis C progression was
established showing the prognosis among HCV infected cohort within different age
groups where the members of each group go through predefined states of health over
one-year time cycles till 2025. The burden of hepatitis C will be estimated through
calculating different transition probabilities and calculating the direct and indirect
healthcare cost of the proportion of members who go through each stage of the
disease and its complications. Under the current management strategy of 125,000
patients/year, it is estimated that chronic active HCV patients will show minimal
decrease to reach about 4.1 million cases, with high economic burden of this strategy
is very high where the direct costs are estimated $23.3 billion, and the total costs are
$48.3 billion between 2015-2025. While increasing the treatment rate to reach one
million patient annually for 5 years in addition to decreasing the annual incidence in
the coming 10 years will drop HCV cases to about 636 thousands by 2025, and with
only $16.2 billion as a direct costs, and total costs $34.2 billion between 2015-2025
which is 29.2% lower than the current management scenario.
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I.

Introduction
Hepatitis C is the most pressing public health challenge in Egypt. According to

World Health Organization (WHO), Egypt has the highest prevalence of hepatitis C
virus (HCV), where the results of blood screening and testing for the Egyptian blood
donors showed 20% positive for HCV (GAR-WHO, n.d.). A recently published Egypt
Health Issues Survey (EHIS) in 2015 on a nationally representative sample showed
that 10% of Egyptians between 15 – 59 years of age had been infected with HCV
infection, while 7% are chronic active hepatitis C patients (Ministry of Health and
Population [Egypt], El-Zanaty and Associates [Egypt], & ICF International, 2015).
This warrants the need to investigate the current and the future burden of this disease
not only from the epidemiological perspective but also from the economic context.
This knowledge is highly important for evaluating the different scenarios of
interventions in order to manage this huge public health problem. Having this
information will make the policy makers in health sectors able to choose the most cost
effective strategy that is capable of reducing the economic and epidemiological
burden of this disease at the country level.
HCV is a RNA virus responsible for the majority of chronic liver disease,
cirrhosis, and Hepatocellular Carcinoma (HCC) cases in Egypt. HCV is transmitted
mainly through exposure to infected blood. Historically, the inadequate sterilization
and reuse of needles in the mass campaigns for treatment of schistosmiasis in Egypt
between 1960s and 1980s were the main risk factors for this huge prevalence of HCV
in Egypt (Nafeh et al., 2000; Rao et al., 2002). Recently, about 60% of the cases were
infected in hospitals and clinics (Yahia, 2011). Also, it was estimated that 24.3% of
patients were infected through blood transfusion, according to EDHS 2008 (Razavi et
al., 2014). Also, some social practices, such as sharing common shaving tools at
barber shops, sharing of home diabetes testing equipment, or toothbrushes are
considerable risk factors outside the health care settings (Yahia, 2011).
HCV is the leading cause of chronic hepatitis, liver cirrhosis and hepatocellular
carcinoma (HCC). About 55%-85% of HCV infected cases become chronic active
cases and pass through the way of developing fibrosis, cirrhosis, and may progress till
1

become decompensated cirrhosis and HCC (‘WHO | Hepatitis C’, 2015).There are
many risk factors affecting the rate of progression from one stage to the following one
in the pathway of the natural history of HCV such as age of the patient, gender,
alcohol consumption, degree of inflammation and fibrosis of liver biopsy, co-infection
with HIV or HBV, and other comorbidities (Chen & Morgan, 2006).
Globally, hepatitis C is a global public health problem where about 130 to 150
million people suffer from chronic HCV (WHO, 2015). It is estimated that HCV
related deaths are 350,000 to 500,000 annually. Mapping the prevalence of HCV all
over the world showed that Africa, Central and East Asia have the highest prevalence
rate (Hanafiah, 2013).
In Egypt, the high prevalence of HCV is not the only problem, the high incidence
of HCV is another important issue which reflects the new HCV infections that occurs
annually. Literature showed that the incidence ranges from 2 to 6.9/1000 annually
which means 160,000 to 500,000 new HCV infection occurs annually (Breban et al.,
2013 ; Miller & Abu-Raddad, 2010). This huge number of newly infected cases made
the problem ongoing and worsen the situation especially with the limited capacities of
Egyptian Ministry of Health and Population (MOHP) for treating those patients,
preventing new infections, and the high cost and low efficacy of old treatment
regimens for HCV.
Although the problem of HCV in Egypt is huge and ongoing, limited data
regarding to the economic and in-depth epidemiological burden of disease were
found. Even with this limitation, the data available regarding the economic burden of
disease in Egypt became outdated especially after the dramatic changes in the key
inputs of the previously published models. The main changes were in the baseline
data of the prevalence of HCV among the different age groups where the previous two
published models used data from DHS 2008, however, a new DHS report was
published recently in 2015. Also, new protocols of treatment were approved by
MOHP which lead to dramatic changes in drug efficacy rather than that used in the
previously published models, in addition to the most recent dramatic decrease in the
drugs prices as well.
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II.

Research objectives:

This thesis aims to cover the following areas:


Estimate the current and future economic burden of HCV in Egypt 2015-2025:
This estimation will include the direct burden of HCV represented in the cost
of HCV treatment regimen, in addition to other medical expenses for
managing different HCV disease progression stages and complications. Also it
will estimate the indirect economic burden of the disease such as disability
adjusted life years (DALYs) to give an estimation for the productivity loss due
to the disease. Also, the monetary value for DALYs will be calculated.



Estimate the current and future epidemiological burden of HCV in Egypt
2015–2025:
This part will give an estimation for all HCV viremia cases across the period
from 2015 to 2015. It also will follow the trend of patients at cirrhosis stage,
hepatocellular carcinoma, and liver related deaths.



Compare the impact of implementing different management scenarios on the
economic and epidemiological burden of HCV in Egypt 2015 – 2025. These
three scenarios are:
o Scenario I: is a mimic for the current situation using the same
treatment rate, cost of current treatment regimen, efficacy of the used
drugs, current incidence rate, and estimate the burden of HCV in the
present and in future if this scenario continue as it is.
o Scenario II: will study the effect of increasing the treatment rate to
treat 500,000 cases per year.
o Scenario III: will discuss the effect of ambitious strategy to treat 1
million cases in the coming five years and decrease the incidence rate
by 50% between 2016-2020, then decrease the incidence rate to
become 10% of the current rate between 2021-2025.

3

III.

Literature Review
A. Natural History of the disease:
1. Causative organism:

Hepatitis C virus is a RNA virus that replicates in the cytoplasm of liver cells, but
is not directly cytopathic (Chen & Morgan, 2006). The virus has a high ability for
replication ranging between 1010 and 1012 virions per day (Neumann et al., 1998).
There are six genotypes of HCV (Boyer et al., 2002),where HCV genotype 4 is the
most common one in Egypt which represents more than 90% of the cases (Kamal,
2007), however, no recent data available about HCV genotype in Egypt as genotyping
is not routinely done to identify the protocol of management. The virus also has more
than fifty subtypes (Chen & Morgan, 2006). HCV genome mutate frequently because
of the weak error proofreading by the viral RNA polymerase in addition to rapid viral
replication (Bukh, Miller, & Purcell, 1995). Numerous subtypes and frequent
mutations have made difficulties in discovering vaccine for HCV till now.
2. Route of transmissions

HCV is a blood borne virus (i.e. the primary mode of transmission is the
exposure to infected blood). Risk factors for transmission of HCV include using
inadequately sterilized medical equipment in health care facilities especially injection
equipment and poorly sterilized surgical instruments, the transfusion of infected blood
and blood products (‘WHO | Hepatitis C’, 2015), inadequate commitment to infection
control measures in hemodialysis units, and injecting drug use through the sharing of
syringes and needles (Chen & Morgan, 2006). Also, some social practices, such as
sharing common shaving tools at barber shops , sharing of home diabetes testing
equipment, or toothbrushes are considerable risk factors outside the health care
settings (Yahia, 2011). A systematic review analysis for the risk of transmission of
HCV from infected mother to her baby showed that the rate of infection was 5.8%
(95% confidence interval [CI], 4.2%–7.8%) for children of HIV-negative women and
10.8% (95% CI, 7.6%–15.2%) for children of HIV-positive women (Benova et al.,
2014). It is rarely transmitted sexually. This vertical transmission increases in Egypt
to reach 36% (5/14) according to a study conducted in Alexandria University Hospital
in Egypt (Kassem, El-Nawawy, Massoud, El-Nazar, & Sobhi, 2000). HCV does not
spread through casual contact such as sharing food or drinks with an infected person,
4

kissing, and hugging. Also it does not spread through food, water or breast milk
(‘WHO | Hepatitis C’, 2015).
3. Disease Progression:

HCV can cause acute and chronic hepatitis. When person has infection by HCV it
develop acute hepatitis, however, most of these cases, around 80%, are asymptomatic.
Only 20% can develop symptoms such as fever, fatigue, nausea, vomiting, decreased
appetite, abdominal pain, dark urine, grey-colored feces, pain in joints and jaundice.
Among those who get infection, the HCV virus is spontaneously cleared in 15% to
45% of cases. Others who do not able to clear HCV by 6 months become chronic
active cases. HCV begin causing fibrosis in the liver which means excessive
accumulation of extracellular matrix proteins including collagen (Bataller & Brenner,
2005). On the long term 15% - 30% of them develop cirrhosis within 20 years. In the
cirrhotic state, advanced fibrosis occurs and liver loses its normal architecture,
however it is still able to do many important functions. Cirrhosis may be developed to
decompensated cirrhosis where the liver becomes unable to do its function well
leading to variceal hemorrhage, ascites, and hepatic encephalopathy. Also, it could
develop hepatocellular carcinoma (HCC) (Figure II1).
Figure III1- Natural history of infection with hepatitis C virus

(Chen & Morgan, 2006)
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There are many variables affect the rate of progression from fibrosis to
compensated cirrhosis, decompensated cirrhosis, and HCC such as age of the patient,
gender, alcohol consumption, degree of inflammation and fibrosis on liver biopsy, and
co-infection with HIV or HBV, and other comorbidities. People who get infected by
HCV in the forties have higher chances of developing fibrosis than those infected at a
younger age (Poynard, Bedossa, & Opolon, 1997). It was found that males who have
daily alcohol consumption 30 g or more are more liable to develop advanced
progression of liver fibrosis, in comparable to 20g/ day for females (NIH, 2002).
Also, it was found that presence of HIV with low CD4 count(CD4<200), and HBV as
well, accelerate the progression of fibrosis in HCV patients (Ragni & Belle, 2001).

B. Treatment of HCV (old treatment Vs. new treatment)
1. Obsolete treatment regimen (low efficacy with high side effects):

Over the past decades, the standard treatment of HCV genotype 4 (HCV- G4)
patient was a combination of pegylated interferon (PEG-INF) and ribavirin (RBV) for
48 weeks (Abdel-Razek & Waked, 2015). The efficacy of this combination to treat
HCV-G4 patient was small. A worldwide study containing 7163 HCV patient treated
by PEG-IFN/RBV showed only 41% sustained virological response (SVR), defined as
aviremia 24 weeks after completion of antiviral therapy for chronic hepatitis C virus
(Marcellin et al., 2012). Also, between 2007 and 2014 the National program for
control of HCV in Egypt has treated about 350,000 patients with this combination
(Doss et al., 2008) and the result showed SVR between 45% and 55% (Esmat et al.,
2014).
2. Direct acting antivirals (DAAs), the new era for HCV treatment (High
efficacy with minimal side effects)

With discovering DAAs that target specific sites in HCV replication
complex, a breakthrough in the efficacy of HCV treatment was introduced. There are
two main classes of DAAs, they differ from each other according to the drug target
site, and subsequently its efficacy against different genotypes. The first discovered
DAAs drugs was S3/S4 protease inhibitors, while the second class of DAAs are
inhibitors of viral polymerase. The first wave of the first generation of protease
inhibitors is potent against HCV-G1 (Poordad et al., 2011) (Bacon et al., 2011)
(Sherman et al., 2011) (Jacobson et al., 2011), but not effective against HCV-G4
(Abdel-Razek & Waked, 2015). That generation included NS3 protease inhibitor and
6

NS4 protease inhibitor (PIs) such as Boceprevir (BOC) and Telaprevir (TVR). Later
on, the second wave of the first generation of PIs was approved for treatment of HCVG4 such as Simeprevir (SIM). The DAAs drugs targeting HCV polymerase includes
NS5B polymerase inhibitors and NS5A inhibitors. NS5B polymerase inhibitors can
be divided into two groups: nucleoside inhibitors (NIs) which mimic the natural
substrates of the polymerase that cause direct chain termination through its
incorporation into the RNA chain (Asselah & Marcellin, 2012), while the other group
is non-nucleoside inhibitors (NNIs) which cause conformational protein change
through binding to one of the sites on HCV polymerase and inhibit the NS5B (Waked
et al., 2014). For example, Sofosbuvir (SOF) was approved as NS5B polymerase
inhibitor drug for treatment HCV-G4, while Daclatasvir (DCV) was approved as
NS5A polymerase inhibitors for treatment HCV-G4 (Figure III2).
Figure III2- New effective drugs against HCV-G4

DAAs

NS3/NS4
Protease
Inhibitors

Polymerase
Inhibitors

NS5B
Polymerase
Inhibitors
e.g. SOF

e.g. SIM

NS5A
Polymerase
Inhibitors
e.g. DCV

3. DAA resistance:

HCV has a high ability for replication ranging between 1010 and 1012 virions per
day (Neumann et al., 1998). The high error rate of NS%B RNA dependent RNA
polymerase leads to the possibility of nucleotide substitution in the HCV genome with
every cycle of replication. This nucleotide substitution may lead to resistance to DAA
which called resistance associated variant (RAVs) (Abdel-Razek & Waked, 2015).
On one hand, SOF has a high genetic barrier for resistance. In subjects who
received SOF in phase III clinical trials, changes in L159F, V321A, and S282T amino
7

acids were identified. L159F and V321A did not influence the activity of SOF, while
S282T caused a reduction in susceptibility to SOF in one patient by 13.5 fold (Han,
Mo, & Wong, 2012).On the other hand, NS%A inhibitors have low barrier for
resistance. Single mutations at Q30E and Y93N confer high levels of resistance to
NS5A inhibitors. These mutations were detected in 4.3% of HCV-4 treatment naiive
patients (McCormick et al., 2014).
Combining DAAs with different targets of activity limits the effect of these
mutations and baseline RAVs. For example, patients who experienced failure of PIs
treatment and had a dominant RAV responded to the combination of SOF/DCV in a
similar manner as those without baseline RAVs (Sulkowski et al., 2014).
4. Guidelines for management HCV-G4 using DAAs drugs:



Guidelines of European Association of Study of Liver diseases (EASL):
The most recent therapeutic guidelines for HCV-G4 published by EASL was

released in July, 2015. These guidelines had six treatment options for managing naiive
and experienced HCV-G4 patients. Two of these options were IFN-containing
regimen while the other four options were IFN-Free regimen as shown in table III-1
(‘EASL Recommendations on Treatment of Hepatitis C 2015’, 2015).
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Table III-1: Summary of EASL recommendations for treatment of HCV-G4
patients, July, 2015:
Regimen

Duration

Option 1:

12 wks.

SOF + PEG-RBV

IFN-containing
Regimen

SIM + PEG-RBV: for 12 wks.
PEG-RBV: for another 12 wks. in naiive and

Option 2:

relapse, and for another 36 wks. For prior

SIM + PEG-RBV

partial and null responders.


Stop treatment: if HCV RNA< 25 IU/ml at
treatment week 4,12 or 24

Option 1:

12 wks.

SOF + Ledipasvir
Option 2:
Rmbitasvir +
Paritaprevir +
Ritonavir
IFN-Free
Regimen



12 wks. :without cirrhosis



24 wks. :with cirrhosis

(± RBV)
Option 3:
SOF + SIM

12 wks.

(± RBV)
Option 4



12wks. : naiive patients

SOF + DCV



24 wks.: patient with cirrhosis and

(± RBV)

contraindication for RBV

(‘EASL Recommendations on Treatment of Hepatitis C 2015’, 2015)



Guidelines of American Association for the study of Liver Diseases (AASLD)
and Infectious Diseases Society of America (IDSA)
In August 2015, AASLD and IDSA have recommended three treatment

options for the management of HCV-G4 cases. They recommended option 1 and 2 of
IFN-Free Regiment in ESAL 2015 guideline, in addition, they also have
recommended SOF and weight based RBV for 24 wks. They also mentioned two
alternatives, the first one was SOF plus PEG/RBV for 12 wks. And the second
9

alternative was SOF + SIM (± RBV) for 12 wks. due to limited supportive clinical
data about this therapeutic option (AASLD/IDSA HCV Guidance Panel, 2015).


Egyptian guidelines
The National Committee for Control of Viral Hepatitis (NCCVH) in May 2015

has adopted one IFN-based regimen and two IFN- free regimen for treatment of
HCV-G4 patients in Egypt. The IFN- based regimen was composed of
SOF+PEG/RBV for 12 wks. For IFN- eligible patient. The second regimen was for
patient ineligible for interferon where the first option was SOF + SIM for 12 wks.,
while the second option was SOF+RBV for 24wks. For patients who have to take
amiodarone or cyclosporine drugs (NCCVH, 2015).The inclusion criteria according to
May 2015 guideline include all HCV RNA positive patients between 18 and 70 years,
either naiive patients or treatment experienced patients without restriction to their
fibrosis stage (NCCVH, 2015).
In November 2015, a new guideline has been published with a significant change
in the treatment regimen. There were two treatment regimen, where the first regiment
was for patients who are easy to be treated, and the second one for patients who are
difficult to be treated. “Easy to Treat” group will get SOF + DCV for 12 wks., while
the “Difficult to be Treat” group will get SOF + DCV +RBV for 12 wks. (Saeed,
2015). The inclusion criteria in November 2015 guideline become the same as the
previous guideline except for the age which increased to include patients from 18 to
75 years (Saeed, 2015).
5. Efficacy of oral DAA combinations:

Using DAAs for treatment HCV-G4 has showed significant increase in cure rate
where SVR has reached nineties in some combinations. For example, in Doss et al.
2015, using SOF + RBV among Egyptian patients with G4 for 24 wks. showed 92%
and 89% SVR among naïve and experienced patients respectively; and SVR among
cirrhotic and non-cirrhotic were and 78% and 93% respectively, with an average SVR
90% ( Doss et al., 2015). In another paper studied the efficacy of triple therapy, SOF+
PEG/RBV for 12 wks., on HCV-G4 showed that SVR was 80% among cirrhotic
while it was 84% among non-cirrhotic, and the total SVR was 83.3% (Wehmeyer et
al., 2015.
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6. Cost of the obsolete regimen versus DAAs regimens:

The last price for the treatment course of PEG-INF/RBV for 48 wks. in Egypt
was about $ 2000. On the other hand, the price of the new DAAs drugs was very
expensive in US and Europe. For example, the initial price of SOF was $84,000 for
12-wk course, and the price of SIM was $ 60,000 for 12-wk course (Fick & Hirschler,
2014), while the Egyptian government succeeded in its negotiation with Gilead
Science to get SOF for 12 weeks at $900 only (Wanis, 2014) (Fick & Hirschler,
2014), and this price became the standard for the India and other developing countries
(Palmer, 2014). Hence, the cost of the triple therapy (SOF+PEG-IFN/RBV) became $
1500 (Abdel-Razek & Waked, 2015). Recently, head of NCCVH declared that the
cost of the whole course of SOF+DCV that has been approved for treatment of HCV
patient in the last treatment protocol in December 2015 will be only $ 319.3 (2500
LE) (Abdelsalam, 2015).

11

C. Epidemiological Burden
1. Global Burden

Hepatitis C is a huge public health problem facing many countries in the world
(Mathurin, 2013). It is estimated that 130 to 150 million people globally suffer from
chronic hepatitis C (WHO, 2015) which comprises about 3% of the world population
(NIH, 2002). A significant number of those patient will develop complications such as
liver cirrhosis and liver cell failure and hepatocellular carcinoma. WHO estimated that
350,000 to 500,000 people die each year from hepatitis C-related liver diseases
(WHO, 2015).
Figure III3- Distribution of HCV all over the world

(Hanafiah, 2013)
Figure III3 shows the prevalence of HCV globally where Africa and Asia (Central
and East) have reported the highest prevalence rates, while North America, Western
Europe, and Australia reported low rates of HCV.
Globally, HCV genotype 1 (HCV-G1) is the most common genotype which
represents about 46% , followed by HCV-G4 with 22%, HCV-G2 with 13%, and G4
with 13%. There is variation in dominance of HCV genotypes across the continents
where HCV-G1is dominant in Europe, North America, south America, and Australia
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which represent 53-71% of all cases; however, G3 is the dominant genotype in Asia
(40%), on the other hand, in North Africa and Middle East G4 is dominant (71%),
however, if Egypt was excluded, G1 will be the dominant (46%) as G1 will decrease
to 34% of all infections in the region (Gower et al., 2014).
2. Burden in Egypt
2.1 Incidence of Hepatitis C

Four studies calculating the incidence of hepatitis C in Egypt by prospectively
assessing cohort of Egyptian regarding positivity and negativity to HCV antibodies,
then follow up the negative people to identify incident cases were reviewed. The first
two studies estimated the incidence among population of rural villages. 6,734
Egyptians living in two rural village in lower and upper Egypt were assessed and
followed up to calculate the incidence of HCV (Mohamed et al., 2005). The incidence
among village resident in Qalubyia, Lower Egypt was 6.8/1,000 person- years, while
the incidence among village residents in Assuit, Upper Egypt governorate was
0.8/1,000 person-years (Mohamed et al., 2005). Another 4 years cohort study were
conducted in Menoufia governorate, Lower Egypt where the incidence was 2.4/1000
PY (95% CI: 1.6–3.5) (Mostafa et al., 2010). The second two studies calculated the
incidence in specific groups such as children and pregnant women. 2852 uninfected
infants from three villages with high HCV prevalence were prospectively followed
from birth for up to 5.5 years where the incidence rate was 2.7/1000 PY (Doa’a et al.,
2008). And for about 2.2 years, 2171 pregnant women in three rural Egyptian village
were followed up to calculate the incidence of HCV among pregnant women. The
results showed that the estimated HCV incidence was 5.2/1000 PY (Doa’a et al.,
2008).
Another two studies built mathematical model to estimate the incidence of HCV
in Egypt. In 2010, Miller et al build their model using age-specific prevalence
extracted from a population based survey, EDHS 2008. The estimated incidence was
6.9/1,000 (95% CI, 5.5–7.4) PY which means that more than 500,000 new HCV case
per year were infected (Miller & Abu-Raddad, 2010). On the other hand, in 2013,
another model was conducted to address the assumption of time-independent
epidemiology to reach more realistic estimate. This model estimated the incidence of
HCV nationwide at around 2.0/1000 PY which means around 150,000 new infections
annually (Breban et al., 2013). The difference between the two models may be due to
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spatial heterogeneity of HCV prevalence and also present different incidence
estimates for young adults.
2.2 Prevalence of hepatitis C
Prevalence in general population

Several studies investigated the prevalence of HCV among general population in
Egypt. In 2008, Egypt Demographic and Health Survey (EDHS) using a national
representative sample estimated the prevalence of HCV to be 14.7% among Egyptian
aged 15-59 years old using HCV antibody test which means that those people had
been exposed to HCV, while the cases with active infection with viremia were 9.8 %
using HCV RNA PCR test (El-Zanaty & Way, 2009). Recently in 2015, the newly
published Egypt Health Issues Survey (EHIS) showed that the prevalence of anti
HCV and HCV RNA among the same age group was 10% and 7%; respectively. By
adding a new age group from 1-14 years to the previous estimate, the prevalence of
anti-HCV and HCV RNA among age group from 1- 59 became 6.3% and 4.4%;
respectively due to low prevalence of HCV among young age people (Ministry of
Health and Population [Egypt], El-Zanaty and Associates [Egypt], & ICF
International, 2015).
According to EHIS 2015, the prevalence of HCV among males are more than
females, and there was a marked difference between age 50-54 and 55-59. For
example, the prevalence of HCV viremia among male and female in age group 55 to
59 was 27.8% and 17.8% respectively. Also, the prevalence of active hepatitis showed
a positive relationship with age where the prevalence among older age groups is much
higher than the younger ones. For example, prevalence of active hepatitis in age
groups below 20 was less than 1% while it reached 22.1% among age group 55-59
years as presented in figure III4.
It was found that the social determinants of health (SDH) such as place of
residence, socioeconomic level and level of education have significant impact on the
prevalence of HCV. According to EHIS 2015, the prevalence of active hepatitis cases
in rural areas was higher than urban areas where it is 5.1% and 3.1%; respectively. In
addition, the prevalence in Lower Egypt governorates is the highest (5.6%), while
urban governorates showed the lowest prevalence (3%). Also, it was clear from the
results that the prevalence of active hepatitis C cases increase with lower wealth
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quintile groups and decrease with the increase of wealth quintile level. For example,
HCV-RNA prevalence among lowest wealth quintile was 5.8%, while it was only
2.6% among the highest wealth quintile (Ministry of Health and Population [Egypt],
El-Zanaty and Associates [Egypt], & ICF International, 2015). Regarding to the
relation between educational level and HCV prevalence, it was found that it is higher
in illiterate people (14.5%) while it was much lower among people who have
completed secondary education and higher (4.1%) (El-Zanaty & Way, 2009).

Figure III4- Prevalence of active hepatitis by age, Egypt 2015

Prevalence among high-risk groups

There are different high risk group for HCV where the prevalence increases
among them. These groups include schistosomiasis patients, patients on hemodialysis
multi-transfused patients, thalassemia patients, IDUs, healthcare workers and barbers.
Treatment of schistosomiasis patients by using parenteral anti-schistosomal therapy
(PAT) campaigns is believed to be the major historic cause for increase the
prevalence of HCV in Egypt (Frank et al., 2000). MOH treated millions of Egyptians
using intravenous tater emetic drugs in between 1950s and 1980s (Strickland, 2006).
During these large scale campaigns, reuse of glass syringe and improper sterilization
measures have caused the HCV epidemic in Egypt (Yahia, 2011). Multiple studies
were conducted to identify the prevalence of HCV among multi-transfused children
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where the average prevalence was 58%. And the average among children with
thalassemia was 58% (Mohamoud et al., 2013). High HCV prevalence rates were
observed with averages of about 42% among multi-transfused children and about 58%
among children with thalassemia. Multiple studies were also conducted among
hemodialysis patients (mostly adults). Very high HCV prevalence was found in both
adult populations and children on hemodialysis. Regarding the prevalence among
hemodialysis patient, 94.1% of them had HCV according to a study conducted in
Mansoura Dakahlia, Lower Egypt (Kassem et al., 2000) , while the prevalence
decreased to 70% in Cairo (Ibrahim, 2010). The burden of disease among healthcare
workers is also high where HCV prevalence was about 17% in average (Mohamoud et
al., 2013). Also it was found that the prevalence among barbers reached 12.3%
(Shalaby et al., 2010).
2.3 Evidence of ongoing transmission
Although Egypt has the highest HCV prevalence in the world, but the most
serious problem is the ongoing transmission of this virus till now. As the capacity of
treatment is less than the incidence rate of HCV. In 2013, Mohamoud et al.
conducted build multiple regression model to follow the trend of HCV prevalence
over time. They built multiple regression analysis which showed no significant
decrease in the prevalence of HCV over time (P-value: 0.215) (Mohamoud et al.,
2013). Recent studies suggest the iatrogenic (healthcare) exposures is the underlying
cause for ongoing transmission of the disease in Egypt (Miller & Abu-Raddad, 2010)
(Talaat et al., 2006).
2.4 Published model for estimating the epidemiological burden:
In 2014, Razafi et al. developed a mathematical model to estimate the present and
future burden of hepatitis C virus. It was the first trial to give in-depth insight about
the epidemiological burden of the hepatitis C in Egypt. A disease progression model
was developed using Microsoft Excel where the model start with new acute hepatitis
C cases that develop chronicity in addition to chronic viremic HCV case. These cases
go through the model and progress from on stage to another according to certain
probabilities as in Figure III5. It moves between different stages of fibrosis (F0, F1,
F2, and F3) till reach cirrhotic stage, then it develop decompensated cirrhosis which
has different forms such as variceal hemorrhage, hepatic encephalopathy, and ascites.
It may develop also hepatocellular carcinoma. The chronic HCV cases may end up
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with cure after getting suitable treatment, liver transplantation, or death due to liver
related mortality (Razavi et al., 2014).
Figure III5- The flow of HCV disease progression model of Razavi et al., 2014

(Razavi et al., 2014)
NC= New Cases , TC= Total Cases
This study showed the burden of the disease in 2013 and the estimated future
burden by 2030 as shown in table III-2.
Table III-2 Estimate of HCV disease burden in 2013 and 2030, in Egypt:
2013 Estimate

2030 Estimate

% change

Viremic HCV infection

5,980,000

4,420,000

( 20)

HCC Cases

16,100

18,300

15

Liver Related Mortality

33,000

36,500

10

Decompensated Cirrhosis

137,000

136,000

(1)

Compensated Cirrhosis

626,000

611,000

(2)
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(Razavi et al., 2014)
One of the main limitations for this model is that it did not take into
consideration the progression of disease in cured cases or spontaneously cured cases
which may got the infection again with HCV. Also it may progress to advanced stages
and develop liver related complications in slower rate despite of viral clearance. This
issue may lead to underestimation for cases of decompensated cirrhosis and
hepatocellular carcinoma as well. Another important issue is that there are many
variables used in this model which have been dramatically changed in the last two
years. First, the drugs available at the time of developing this model for treatment
HCV were pegylated interferon (Peg-INF) and ribavirin (RBV) which have many side
effect and contra indications for this treatment, therefor, only 40% to 60% of HCV
patient were eligible for getting Peg-INF/ RBV (Morrill, Shrestha, & Grant, 2005).
Second, the Sustained Viral Response (SVR 24) which defined as aviremia 24 weeks
after completion of antiviral therapy for chronic HCV infection (Pearlman & Traub,
2011), this SVR for Peg-INF/ RBV was 48% (Razavi et al., 2014), which means that
only 48% of people who received this regimen were cured. However, nowadays after
discovering Sofosbuvir (SOF) the SVR 12 for the triple therapy containing SOF, PegINF/ RBV for 12 weeks is 83.3% (Wehmeyer et al., 2015) and 90% for dual therapy
containing SOF and RBV for 24 weeks (Doss et al., 2015) with average 86.65%.
Third, the number of annually treated patient in Egypt used in this model was 65,000
patient per year where 77% of them got their treatment in the liver treatment centers
affiliated to Ministry of Health and Population (Doss et al., 2008),15% of them got
their treatment from Health Insurance Organization (HIO), and 8% of them got their
treatment as out of pocket. However, recently the number of people receiving the
treatment annually has increased to 125,000 patients per year (Donald, 2015).
Two recent studies addressed estimation for the current and the future burden
of HCV in Egypt when applying different scenarios regarding to treatment rate and
treatment efficacy. In 2014, Waked et al used the previously illustrated mathematical
model developed by Razavi et al (Razavi et al., 2014). This paper studied three
scenarios where the basic one assume fixed number for annually treated patient,
eligible patient for treatment, the number of newly diagnosed patient between, and
efficacy of the drugs, 2013 till 2030 (Waked et al., 2014). The second scenario
assumed increasing efficacy of the drugs to become 90% rather than 48% in the first
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scenario, and increasing the percentage of people eligible for getting the treatment to
reach 90% compared to 50%, while the third scenario assumed increasing the drug
efficacy and treatment eligibility such as previous scenario, in addition to increasing
the treatment rate to reach 325,000 patient by 2018 rather than 65,000 in the second
scenario (Waked et al., 2014). The impact of each scenario are shown in table III-3
Table III-3 The impact of different treatment scenarios on the morbidity and
mortality of HCV, in Egypt:
2013
Estimate

No. of total infected

6,000,000

% of change from 2013
No. of compensated cirrhosis

630,000

% of change from 2013
No. of decompensated cirrhosis

138,000

% of change from 2013
No. of HCC

16,000

% of change from 2013
No. of HCV related Mortality

33,000

% of change from 2013

2030 Estimate
Scenario

Scenario

Scenario

(1)

(2)

(3)

4,420,000

4,045,000

280,000

-26%

-32%

-95%

610,000

507,000

76,000

-2%

-19%

-88%

136,300

110,000

17,000

-0.6%

-21%

-87%

18,500

16,000

2,400

+15%

0%

-85%

36,500

30,700

7,500

+10%

-7%

-77%

(Waked et al., 2014)
Regarding to the design of this model, our previously mentioned criticism is
still valid as Waked et al., 2014 used the model of Razavi et al., 2014 as is. Although
the authors updated some of data used in the model, these data become now outdated.
For example, they added the SVR of the new DAA drugs that have reached phase II
and phase III clinical trials and are expected to be in the market soon. They expected
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SVR for this new drugs at that time to be 90%, however the recent studies showed
that the SVR for these drugs after using it on large scale to range from 83.3% for
triple therapy (Wehmeyer et al., 2015) to 90% for dual therapy (Doss et al., 2015)
with average 86.65%. Another issue, the inclusion criteria used in this paper for the
persons eligible for treatment were age form 15-59 years old, and the histological
state of liver fibrosis was more or equal to F2, however the current inclusion criteria
published in May 2015 included wider age group from 18-70 years old, and also
include all fibrotic stages including F0 and F1 which will lead to changes in the
outcomes of the model (NCCVH, 2015).
The second study addressed the estimation of the current and the future burden
of HCV in Egypt when applying different scenarios regarding to treatment rate and
treatment efficacy was conducted by Shelbaya et al., 2015. They developed Markov
model to model the transition of HCV infected cohort among different age groups
using Egyptian DHS 2008 through following them up over time. In this Markov
model, members of the cohort go through predefined states of health over a period of
time where the patients move between different health states of the liver disease such
as F0, F1, F2, F3, compensated cirrhosis, and complication and liver related death
according to specific probabilities. Then the burden of HCV (morbidity and mortality)
was estimated for the cohort.
The results of the model showed that the current treatment rate for about
65,000 patient/ year will lead to increase the annual number of HCV related deaths in
Egypt from about 15,000 deaths/year in 2015 to about 40,000 deaths/year by 2030
(Shelbaya et al., 2015). Also, all cirrhotic cases is expected to increase from 750,000
cases in 2015 to reach the peak by 2022 where it will be 925,000 cases then slightly
decrease to reach 800,000 cases by 2030 (Shelbaya et al., 2015). The paper showed
that with the increase the rate of treatment to 8% i.e. treating 300,000 - 450,000
patients the expected total viremic HCV cases will reach 1,000,000 cases by 2030,
number of liver related deaths will be lower than 15,000 deaths, and the number of
patients with cirrhosis will decline by 87 % to reach about 100,000 cases by 2030
(Shelbaya et al., 2015).
Although this model tried to mimic the natural history of the disease and the
possible progression events that could happen, however, there are some issues
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regarding the design of the model. First, according to the model, the patient who got
the treatment and not cured they either stay in the same health state or progress to the
next one, where it is possible to get the treatment another time which may lead to
overestimate for the economic burden of the disease. Second, one of transition states
in the model for health states F0, F1, F2, F3, F4, compensated cirrhosis, and
decompensated cirrhosis health states was “New Incidence” transition state which
represents the probability of developing new incident case from the previous health
state. However, this probability to develop new incident case should be allocated only
to susceptible individuals who are HCV free or cured and should not be allocated to
individuals with the disease.
D. Economic burden
Limited literature were found covering the aspect economic burden of HCV in
Egypt. The two previously reviewed models in this paper of Razavi et al. 2013 and
Shelbaya et al. 2015 were used to estimate the current and future economic burden of
HCV in Egypt.
In Estes et al., 2015 model, the direct health care cost and indirect burden of
HCV in Egypt was calculated between 2013 and 2030 through using the model
established by Razavi et al. 2013 , where direct health care cost was calculated based
on data collected from the National Liver Institute which is a representative of
governmental hospitals. Also, indirect costs were estimated based on calculating
disability adjusted life years (DALYs) which includes years of life lost to disability
(YLD) and years of life lost due to premature death (YLL); in addition the value of
lost productivity was estimated using Egyptian estimates for the value of a statistical
life year (VSLY). The same previously used scenarios in Waked et al., 2014 to
estimate the economic burden were used by Estes et al., 2015 to calculate the
economic burden as well, where the first scenario had the old treatment with 48%
SVR and treated cases annually is about 65,000; the second scenario with 90% SVR
and 65,000 treated cases annually; while the third scenario had 90% SVR and 325,000
treated cases annually.
The results of the model presented in Table III-4 showed that the old regimen
of treatment and number of annually treated burden will result in $ 89.1 billion as a
cumulative total cost for HCV, however the new introduced HCV drugs with high
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SVR will decrease the burden by 3.7%, while increasing the rate of treatment using
this drugs as in scenario no. 3 will cause significant decrease in the burden of HCV by
35.4% to reach $57.6 billion (Estes et al., 2015).
Table III-4 Direct and indirect costs by Scenario – Egypt, 2015–2030
Scenario (1)
Cumulative disability adjusted

7,875,440

Scenario (2)

Scenario (3)

7,343,640

4,923,210

-6.8%

-37.5%

24,192,586,440

18,632,607,710

4.1%

-19.8%

61,547,348,360

38,929,874,750

-6.5%

-40.9%

85,739,934,800

57,562,482,460

-3.7%

-35.4%

life years 2013–2030
% of change from scenario (1)
Cumulative direct costs

23,244,377,860

2013–2030 (US $)
% of change from scenario (1)
Cumulative indirect costs

65,822,552,110

2013–2030 (US $)
% of change from scenario (1)
Cumulative total costs 2013–2030

89,066,929,970

(US $)
% of change from scenario (1)
(Estes et al., 2015)

Shelbaya et al., 2015 model showed that the estimated cost of applying policy
of 1% treatment rate will be $600 million in 2015 then decline to $500 million by
2030 where all viremic HCV cases will decline by 15% to reach about 5.5 million
cases, while with 5% treatment rate it decline from at $900 million in 2015 to $550
million by 2030 where this policy will lead to decrease the all viremia cases by 61%
to reach 2.5 million cases (Shelbaya et al., 2015). However, the cost of treatment of
the suggested policy by the paper, 8% treatment rate, was $ 1.3 billion in the first year
of treatment then decrease gradually to reach $ of $580million by 2030, where all
viremia cases will decrease by 84.6% to reach 1 million cases by 2030 (Shelbaya et
al., 2015).
On one hand, in Shelbaya et al. 2015, the cost of the treatment was updated to
match the new prices of the new drugs available for treatment HCV. On the other
hand, all the estimates of the cost data were based on expert opinion from a Delphi
panel of local experts. Also, it is not clear if this is the cost of triple regimen or the
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dual regimen as the available published model is just poster presentation, therefore
did not contains much detailed information. Another comment regarding to the cost
estimate is that the cost estimate for liver transplant in first year is very small ($
1.197), as the cost of liver transplant surgery is much higher than this cost. According
to Khalaf et al., 2005 the cost of living donor liver transplantation (LDLT) in a private
based hospital is about $ 70,000 while it reaches $ 25,000 in governmental hospital,
also a recent estimate in 2015 showed that the cost is about $ 42,000 according to data
collected from the National Liver Institute (NLI), a nationally representative
government hospital (Estes et al., 2015). This very low cost estimate for liver
transplant may lead to underestimation of the real burden of the diseases.

E. Other types of disease burden:
Lack of awareness about Hepatitis C in the community often leads to
misinformation, missing of opportunities for prevention and treatment, and
stigmatization of infected populations. level of support that someone with chronic
hepatitis C might receive was less when compared to someone with a chronic illness
that does not carry a stigma which might affect self-esteem and cause decrease in the
quality of life (Ibrahim & Madian, 2011). This stigma of the disease push 30.9% of
the patients to conceal the nature of their illness and 24.4% of them even conceal this
information from their families, according to a study conducted in Elghar village,
Zagazig governorate (Eassa et al., 2007). Also, HCV patients are not allowed to travel
to gulf countries for work. This opportunity lost due to inability of traveling for
working in certain countries are not included in our analysis in the thesis.

F. National Strategy for Prevention and Control 2014-2018
As Egypt is the highest country in the world in the prevalence of HCV, World
Health Organization (WHO) has called experts from head quarter in Geneva, Center
of Disease Control and Prevention (CDC) in U.S, NAMRU-3, and Institut
Pasteur/Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS)
to support Egypt in building a comprehensive national strategy for prevention and
control of HCV. Multiple mission in different specialties visited Egypt to conduct gap
analysis, then began in cooperation with MOH official and Egyptian NGOs to
establish “Plan of Action for the Prevention, Care and Treatment of Viral Hepatitis,
Egypt, 2014-2018” (MOHP, 2014).

23

The plan of action is composed of seven pillars to ensure efficient prevention
and control of viral hepatitis. The first pillar aimed to strengthen national surveillance
system for viral hepatitis to follow the trend of the disease, identify risk factors, and
measure the impact of implementation of the prevention and control program. The
second pillar is focused on infection control where it aimed to decrease transmission
of viral hepatitis through health care facilities, promote safe injection, and strengthen
monitoring and evaluation program to ensure proper implementation for infection
control measures. The third pillar focused on blood safety through different activities
such as establishing national standards for blood transfusion and management,
enhance the capacities of blood banks in blood screening and testing, capacity
building for staff working in blood banks, and developing IT component to increase
safety of collected blood and enhance blood management system. The fourth pillar is
focused on vaccination against Hepatitis B where it aimed to achieve universal
vaccination among high risk groups, and ensure implementation of zero dose of
against HBV for all newborn in the first 24 hours after birth. The fifth pillar is
concerned with raising awareness regarding to mode of transmission and methods of
prevention among community. The sixth pillar is dedicated to ensuring availability
and accessibility of effective drugs for treatment of viral hepatitis. The seventh pillar
is concerned with scientific research to fill the gap in knowledge in hepatitis issues,
and translate this knowledge into policies and practices (MOHP, 2014).
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IV.

Methodology:
A. Model Description
A model representing hepatitis C progression was established by using

Markov model showing the prognosis among HCV infected cohort within different
age groups using Egyptian DHS 2015 results, then following each age group cohort
between 2015-2025. In this Markov model, the members of each age group go
through predefined states of health over one-year time cycles till the end of the
predefined period of time to 2025. The current and future epidemiological burden
(morbidity and mortality) and economic burden as well of hepatitis C will be
estimated through calculating different transition probabilities and calculating the
direct and indirect healthcare cost of the proportion of members who go through each
stage of the disease and its complication.
First, all Egyptian population between 1-59 years will be divided according to
their age into 5 years interval age groups. Then, each cohort will move through the
same health states with different probabilities according to the age. The health states
were based on presence or absence of hepatitis C viremia, liver histology,
decompensated liver disease, hepatocellular carcinoma, or liver transplantation. The
hepatic patient has three histological states based on Metavir classification, F0, F1, F3
and cirrhotic stage. Over a period of time the patient go from a stage to the following
or stay at his stage. For example, patient in F0 state after one year could become in F1
stage or stay at F0 stage and so on. The data required for this model such as
probability of transmission from stage to another, cost of health care services and
utilities of different health states will be gotten from literature and will described in
details in “Model Input” section. Annex 1 contains the model structure.
The health states included in the models are:


HCV free population: This group includes all the people in this age group who
are not suffering from Viremic HCV, while the following health states
includes patients who has HCV viremia



F0_treatment: This group includes the people in this age group who have
viremia and their histology according to Metavir criteria showed that they
have no fibrosis (F0 stage) (Goodman, 2007). Also, the patient in this age
group may get or not get the treatment according to many scenarios such as
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probability of diagnosis and availability of drug and eligibility for going
through the treatment protocols


F0_ treatment failure: This group includes the people in this age group who
have viremia and their histology according to Metavir criteria showed that
they have no fibrosis (F0 stage) , and they got HCV treatment previously;
however, they did not show SVR (i.e. treatment failure)



F1_ treatment: This group includes the people in this age group who have
viremia and their histology according to Metavir criteria showed that they
have portal fibrosis without septa (F1 stage) (Goodman, 2007). Also, the
patient in this age group may get or not get the treatment according to many
scenarios such as probability of diagnosis and availability of drug and
eligibility for going through the treatment protocols



F1_ treatment failure: This group includes the people in this age group who
have viremia and their histology according to Metavir criteria showed that
they have portal fibrosis without septa (F1 stage), and they got HCV treatment
previously; however, they did not show SVR (i.e. treatment failure)



F2_ treatment: this group includes the people in this age group who have
viremia and their histology according to Metavir criteria showed that they
have portal fibrosis with few septa (F2 stage) (Goodman, 2007). Also, the
patient in this age group may get or not get the treatment according to many
scenarios such as probability of diagnosis and availability of drug and
eligibility for going through the treatment protocols



F2_ treatment failure: This group includes the people in this age group who
have viremia and their histology according to Metavir criteria showed that
they have portal fibrosis with few septa (F2 stage), and they got HCV
treatment previously ; however, they did not show SVR (i.e. treatment failure)



F3_ treatment: This group includes the people in this age group who have
viremia and their histology according to Metavir criteria showed that they
have portal fibrosis with numerous septa without cirrhosis (F3 stage)
(Goodman, 2007). Also, the patient in this age group may get or not get the
treatment according to many scenarios such as probability of diagnosis and
availability of drug and eligibility for going through the treatment protocols.
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F3_ treatment failure: This group includes the people in this age group who
have viremia and their histology according to Metavir criteria showed that
they have portal fibrosis with numerous septa without cirrhosis (F3 stage), and
they got HCV treatment previously; however, they did not show SVR (i.e.
treatment failure)



Compensated Cirrhosis: This group includes the people in this age group who
have viremia and the liver has irreversible diffuse disorganization of its
normal structure (El Saadany et al., 2005); however, it is still able to perform
many important functions (Franciscus, 2015). Also, the patient in this age
group may get or not get the treatment according to many scenarios such as
probability of diagnosis and availability of drug and eligibility for going
through the treatment protocols



Compensated Cirrhosis with treatment failure: This group includes the people
in this age group who have viremia and the liver has irreversible diffuse
disorganization of its normal structure (El Saadany et al., 2005) ; however, it
is still able to perform many important functions (Franciscus, 2015) Also, the
patient in this age group may get or not get the treatment according to many
scenarios such as probability of diagnosis and availability of drug and
eligibility for going through the treatment protocols. The patients in this group
got HCV treatment previously ; however, they did not show SVR (i.e.
treatment failure)



Diuretic Sensitivity Ascites: This group includes the people in this age group
who have viremia and decompensated cirrhosis where the liver is extensively
scarred and unable to do its function well (Franciscus, 2015), which leads to a
measurable accumulation of intra-abdominal fluid due to the increase in portal
venous pressure(El Saadany et al., 2005),and this ascites can be treated with
dietary sodium restriction and oral diuretic (Arroyo et al., 1996)



Diuretic Refractory ascites: This group includes the people in this age group
who have viremia and decompensated cirrhosis where the liver is extensively
scarred and unable to do its function well (Franciscus, 2015), which leads to a
measurable accumulation of intra-abdominal fluid due to the increase in portal
venous pressure (El Saadany et al., 2005), however, this ascites cannot be
treated with dietary sodium restriction and oral diuretic (Arroyo et al., 1996).
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Variceal Hemorrhage: This group includes the people in this age group who
have viremia and decompensated cirrhosis induced portal hypertension
(El Saadany et al., 2005)



Hepatic Encephalopathy: This group includes the people in this age group who
have viremia and decompensated cirrhosis that characterized by changes in
personality, intellectual impairment, and alteration in level of consciousness
(‘Hepatic Encephalopathy’, 2015)



Hepatocellular Carcinoma: This group includes the people in this age group
who have viremia and cirrhosis with a primary malignancy of the liver cells
(‘Hepatocellular Carcinoma’, 2015)



Liver Transplant 1st Year: This group includes the people in this age group
who have had conducted liver transplantation operation during this year.



Liver Transplant Subsequent Year: This group includes the people in this age
group who have had conducted liver transplantation operation in the previous
year or years



Cured: This group includes the people in this age group who cured from HCV
either spontaneously or by HCV treatment and they do not have cirrhosis



Cured with Cirrhosis: This group includes the people in this age group who
cured from HCV when they got HCV treatment, however, they do developed
cirrhosis



Liver Related Deaths: This group includes the people in this age group who
died as a consequence to HCV disease



Death from Background Mortality: This group includes the people in this age
group who died due to any other causes rather than HCV disease.

The current and future burden of HCV with the different policies will be estimated
in the form of epidemiological and economic burden. In epidemiological burden we
will follow all viremia cases, cirrhosis, HCC, and liver related deaths over the coming
15 years. On the other hand, we will estimate the economic burden in the form of
direct expenses that includes cost of treatment, consulting physicians, hospital
admissions, and laboratory investigations. In addition to direct heath care cost, the
indirect cost will be calculated as well. This indirect cost will be identified by
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calculating Disability Adjusted Life Years (DALYs) which includes years of life lost
due to disability (YLD), and years of life lost due to premature death (YLL).
This model will be designed and analyzed by using “TreeAge Pro 2015”
software application https://www.treeage.com/

B. Different scenarios
After establishing this model we will compare between three scenarios for control
of HCV in Egypt where:


The first scenario: is a mimic for the current situation using the same treatment
rate, cost of current treatment regimen for 125,000 cases, efficacy of the used
drugs, current incidence rate, and estimate the burden of HCV in the present
and in future if this scenario continue as it is. In this scenario, we used the
triple and dual therapy for treating HCV cases in 2015 and use the recent
treatment protocol published in December 2015 by NCCVH that depend on
SOF and DCV for treating cases starting from 2016 (Saeed, 2015).



The second scenario: will study the effect of increasing the treatment rate to
treat 500,000 cases per year starting from 2016 with using the recent treatment
protocol published in December 2015 by NCCVH that depend on SOF and
DCV±RBV for treating cases starting from 2016 (Saeed, 2015).



The third scenario: will discuss the effect of ambitious strategy to treat about 1
million cases in the upcoming five years and decrease the incidence rate by
50% between2016-2020, then decrease the incidence rate to become 10% of
the current rate. We also will use the recent treatment protocol published in
December 2015 by NCCVH that depend on SOF and DCV±RBV for treating
cases starting from 2016 (Saeed, 2015).

C. Model Input:
1. Population:
The data of the population was based on data collected from “Egypt Statistical
Year Book,2015” produced by Egyptian Central Agency for Public Mobilization and
Statistics (CAPMAS).The population was divided into age groups with 5 year
intervals (CAPMAS, 2015). We gathered people who were 60 years or older in one
group. Table IV-1 presents the population data used in the model.
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2. Prevalence
The data of HCV prevalence was based upon results of the EHIS 2015. The
EHIS 2015 had a nationally representative sample of Egypt. Among 842 primary
sampling units (PSUs) (shiakhas/villages) from 25 governorates 624 PSUs were
selected. Then household list in the sample were prepared and approximately 28,500
individuals between 6 months and 59 years were identified for interviews and testing
for HCV (Ministry of Health and Population [Egypt], El-Zanaty and Associates
[Egypt], & ICF International, 2015). Two different types of laboratory tests were
conducted, HCV antibody and HCV RNA. We used the results of HCV RNA as it
represents the chronic active hepatitis cases. Results were presented in five-year age
groups for individuals from 1- 59 year (Table IV-1). The prevalence of HCV RNA for
individual aged 1- 59 was 4.4%. The prevalence for people aged sixty years and
above was assumed to be as equal as those in the age group 55-59 years.
Table IV-1 Distribution of Egyptian population and HCV RNA positive cases by
age, 2015
Age Group

Population
number *

Probability of
Healthy Population

Probability of HCV
RNA (+ve) cases **

0- 04

9830000

0.9980

0.0020

05-09

9126000

0.9995

0.0005

10-14

8184000

0.9970

0.0030

15-19

8389000

0.9920

0.0080

20-24

8929000

0.9780

0.0220

25-29

8399000

0.9700

0.0300

30-34

6731000

0.9510

0.0490

35-39

5281000

0.9400

0.0600

40-44

4740000

0.9100

0.0900

45-49

4350000

0.8870

0.1130

50-54

3777000

0.8010

0.1990

55-59

3084000

0.7790

0.2210

>=60

5,993,000

0.7790

0.2210

*Data from Egypt statistical yearbook, 2015 (CAPMAS, 2015). ** Data from Egyptian Health
Issues Survey, 2015 (Ministry of Health and Population [Egypt], El-Zanaty and Associates
[Egypt], & ICF International, 2015)
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3. Incidence
We used the most recent estimate for the incidence of HCV in Egypt of
Breban et al. 2013, where a nationally represented data were used to give a realistic
incidence for HCV. This model estimated the incidence of HCV nationwide around
2.0/1000 PY which means that there are150,000 new HCV infections annually
(Breban et al., 2013).

4. Baseline health states
2.1 Liver Fibrosis (F0, F1, F2, F3)

The data of the baseline or initial probabilities of different stages of liver
disease in each age group was based on data from Wong et al. 2000 paper for
estimating the burden of HCV in United States (Wong et al., 2000). As we used
Metavir classification for the grade of live fibrosis in our model, we divided the
allocated probability of the baseline value of mild hepatitis in Wong paper equally
between F0 and F1; while the allocated value for moderate hepatitis was equally
divided between F2 and F3 (table IV-2). These baseline probabilities were calculated
after taking into consideration the baseline probabilities of HCV related deaths and
HCC.
Table IV-2 Baseline probabilities of different fibrosis stages by age
Age Group

F0

F1

F2

F3

0- 04

0.00100

0.00100

0.00000

0.00000

05-09

0.00025

0.00025

0.00000

0.00000

10-14

0.00149

0.00149

0.00001

0.00001

15-19

0.00396

0.00396

0.00004

0.00004

20-24

0.00979

0.00979

0.001210

0.001210

25-29

0.01335

0.01335

0.001640

0.001649

30-34

0.01737

0.01737

0.00538

0.00538

35-39

0.02125

0.02125

0.00659

0.00659

40-44

0.02236

0.02236

0.01431

0.01431

45-49

0.02790

0.02790

0.01786

0.01786

50-54

0.02855

0.02855

0.04234

0.04234

55-59

0.03144

0.03144

0.04662

0.04662

>=60

0.00254

0.00254

0.05204

0.05204

31

2.2 Liver Cirrhosis (Compensated and Decompensated):

Regarding the baseline probability of liver cirrhosis, we based also on the
value of Wong et al. 2000 paper after dividing it between compensated liver cirrhosis
and decompensated states of liver cirrhosis such as, ascites, variceal hemorrhage, and
hepatic encephalopathy based on data from Asrani et al. 2014 research. In Asrani et
al. 2014, a study conducted in Mayo Clinic for patients with advanced fibrosis
undergoing magnetic resonance elastography between 2007–2011. During this period,
430 patients were diagnosed as having advanced fibrosis and/or diagnosed clinically
to have cirrhosis (Asrani et al., 2014). The baseline analysis for this cohort showed
that 68% are compensated cirrhotic patient while 32% have evidence of
decompensated cirrhosis including ascites, variceal hemorrhage, or hepatic
encephalopathy (Asrani et al., 2014). Among people who met the criteria of
decompensated cirrhosis, 60.44% suffered from ascites, 20.33% of decompensated
cirrhotic patient had variceal hemorrhage, and 19.23% had hepatic encephalopathy
(Asrani et al., 2014). Hence, the predicted prevalence of cirrhosis in (Wong, 2000)
according to age group were divided as follow, 68% of this value allocated for initial
probability for compensated cirrhosis state, 19.34% of it for initial probability for
ascites patients, 6.51% allocated for variceal hemorrhage state, and 6.15% for the
baseline probability for hepatic encephalopathy state (Table IV-3 )..
Table IV-3 Baseline probabilities of compensated cirrhosis and different
decompensated cirrhosis states by age
Age Group

Compensate
d Cirrhosis

Variceal
Hemorrhage

Diuretic
Sensitivity
Ascites

Diuretic
Refractory
Ascites

Hepatic
Encephalopa
thy

0-04

0.00000

0.00000

0.000000

0.000000

0.00000

05-09

0.00000

0.00000

0.000000

0.000000

0.00000

10-14

0.00000

0.00000

0.000000

0.000000

0.00000

15-19

0.00000

0.00000

0.000000

0.000000

0.00000

20-24

0.00000

0.00000

0.000000

0.000000

0.00000

25-29

0.00000

0.00000

0.000000

0.000000

0.00000

30-34

0.00233

0.00022

0.000331

0.000331

0.00021

35-39

0.00285

0.00027

0.000405

0.000405

0.00026

40-44

0.01095

0.00105

0.001557

0.001557

0.00099
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45-49

0.01366

0.00131

0.001943

0.001943

0.00124

50-54

0.03750

0.00359

0.005332

0.005332

0.00339

55-59

0.04129

0.00395

0.005871

0.005871

0.00373

>=60

0.07322

0.00701

0.010413

0.010413

0.00662

2.3 HCC:

In 2015, the number of hepatocellular carcinoma (HCC) due to HCV was
estimated at 17,000 cases (Waked et al., 2014). Based on a retrospective study that
reviewed the data of HCC patients who attended the outpatient clinic of HCC Unit,
Ain Shams University Hospitals, Cairo, Egypt between January 2009 and December
2011 (Shaker et al., 2013), and the distribution of HCC patients among the different
age groups, the baseline probability of HCC among each age groups was calculated to
keep the ratio between age groups as it was in the Ain Shams Study (Table IV-4).
Table IV-4 Baseline probabilities of HCC and Liver related deaths by age
Age Group

HCC

Liver Related Death

0-04

0.00000

0.00000

05-09

0.00000

0.00000

10-14

0.00000

0.00000

15-19

0.00000

0.00000

20-24

0.00001

0.00000

25-29

0.00001

0.00000

30-34

0.00003

0.00003

35-39

0.00003

0.00010

40-44

0.00044

0.00011

45-49

0.00048

0.00090

50-54

0.00103

0.00104

55-59

0.00126

0.00290

>=60

0.00078

0.00283
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5. Disease progression probabilities

Disease progression probabilities were based on back-calculated progression
rates conducted by Razavi et al. 2013 for data US and UK data. The fibrosis
progression rate between F0 to F1, F1 to F2, F2 to F3, F3 to cirrhosis, F3 to HCC, and
cirrhosis to HCC were based on data collected from the US Surveillance,
Epidemiology and End Results program between 1999-2009. As the collected data in
Razavi et al. 2013 for fibrosis were classified by gender, we calculated the average
progression probabilities between male and female. Also, we reduced the progression
probability rate from F1 to F2 by 20% due to lower alcohol consumption in Egypt
incomparable to US and UK which considered one of the factors that accelerates the
progression rate. In addition, the probabilities for the age group 60 years and above
were calculated as an average for the probabilities of all age groups from 60 years to
more than 85 years mentioned in the same paper (Table IV-5). Other probabilities of
spontaneous clearance, progression from diuretic sensitivity ascites to diuretic
refractory ascites, different decompensated cirrhotic states to liver related deaths,
HCC to death, and from liver transplant to death were collected from literature (Table
IV-6).
Table IV-5 HCV Annual disease Progression probability by age
Age Group

From F0 to
F1

From F1 to
F2

From F2 to
F3

From F3 to
Cirrhosis

From F3 to
HCC

From
Cirrhosis
to HCC

0-04

0.0485

0.0280

0.0495

0.0000

0.0000

0.0030

05-09

0.0485

0.0280

0.0495

0.0000

0.0000

0.0030

10_14

0.0590

0.0344

0.0605

0.0070

0.0000

0.0030

15-19

0.0590

0.0344

0.0595

0.0070

0.0000

0.0030

20-24

0.0475

0.0276

0.0485

0.0230

0.0000

0.0030

25-29

0.0475

0.0276

0.0485

0.0230

0.0000

0.0030

30-34

0.0345

0.0200

0.0430

0.0520

0.0000

0.0045

35-39

0.0345

0.0200

0.0430

0.0520

0.0000

0.0045

40-44

0.1275

0.0740

0.1310

0.0810

0.0005

0.0080

45-49

0.1275

0.0740

0.1310

0.0810

0.0005

0.0080

50-54

0.1570

0.0912

0.1605

0.0440

0.0010

0.0130

55-59

0.1570

0.0912

0.1605

0.0440

0.0010

0.0130

>=60

0.1840

0.1334

0.1886

0.1414

0.0021

0.0304
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Table IV-6 HCV Annual disease Progression probability
From

To

Acute HCV

Spontaneous Cure

Progression
probability
0.175

Incident case

Fulminant

0.005

Cirrhosis

Diuretic Sensitive Ascites

0.025

Cirrhosis

Hepatic encephalopathy

0.004

Cirrhosis

Liver transplant

0.0015

Cirrhosis

Variceal Hemorrhage

0.0011

Diuretic Sensitive Ascites

Diuretic Refractory
Ascites
Liver related death

0.067

Liver related death

0.33

Liver related death, year 1

0.4

Liver related death,
subsequent years
Liver related death, year 1

0.13

Liver related death,
subsequent years
Liver related death, year 1

0.4

Diuretic Sensitive Ascites
Diuretic Refractory
Ascites
Variceal Hemorrhage
Variceal Hemorrhage
Hepatic encephalopathy
Hepatic encephalopathy
Hepatocellular carcinoma
Hepatocellular carcinoma
Liver Transplant
Liver Transplant
Decompensated Cirrhosis

6.

Source
(El-Attar et
al., 2010)
(El Saadany
et al., 2005)
(El Saadany
et al., 2005)
(El Saadany
et al., 2005)
(Shelbaya et
al., 2015)
(El Saadany
et al., 2005)

0.11

(Razavi et
al., 2014)

0.68

0.707

Liver related death,
subsequent years
Liver related death, year 1

0.162

Liver related death,
subsequent years
Liver Transplant

0.057

0.21

0.031

(Wong et al.,
2000)
(El Saadany
et al., 2005)

Liver related Deaths

It was estimated that the liver related deaths in 2015 was around 35,000 cases.
For estimating the annual rate of liver related deaths by age group, we used the annual
rate of liver related deaths collected by US 2013 surveillance of viral hepatitis
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(Division of Viral Hepatitis, CDC, 2015); then this rate was adjusted to reach the
35,000 liver related deaths in Egypt keeping the ratio between age groups as it is in
US 2013 data of surveillance of viral hepatitis. Table IV-1 show the probability of
liver related deaths by age group used in our model.
7. Probability of death from background

This model take into consideration the probability of death from other causes. As this
probability is different according to different age groups. We have extracted the
mortality rate of each age group of Egypt from Global Health Observatory (GHO)
data repository of WHO (GHO-WHO, 2013). Then, probability of background
mortality was calculated for each age group through using the following equation:

Probability= 1- exp

(-rt)

where r express for rate and t express for time. The probability of background
mortality, used in this model, are shown in Table IV-10.
8. Direct costs

The data for the direct cost of medical expenses including HCV drugs and
other medical care expenses according to different stages of liver disease were
collected from different literatures between 2014 and 2015 that based on Egyptian
context. The prices of HCV drugs were based on the prices of these drugs for the
government (Table IV-7). Regarding to the cost of the IFN- based regimen (SOF
+PEG-IFN/RBV) for 12 weeks, it was 9600 LE which is equal $ 1,226 (Esmat, n.d.),
while the cost of IFN- free regimen (DualTherapy) for 24 wks.was 12,600 LE which
is equal $1,609 (Esmat, n.d.); therefore the average of the cost of this regiment which
was used in 2014 for treatment HCV patients was $ 1417.5.
As the economic burden will be estimated over a long period of time cost
adjustment will be applied through applying 3% discounting rate.
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Table IV-7 Annual Cost of different states of HCV in US $
Variable
First Year after Following Year
Data Source
Diagnosis $
$
Cost of medical Care of
838
424
F0, F1, F2, or F3 *
Cost of medical Care of
654
602
Cirrhosis *
Cost of medical Care of
Decompensated Cirrhosis
(Obach et al., 2014)
1184
1179
(Ascites, Variceal
Hemorrhage, or Hepatic
Encephalopathy )*
Cost of medical Care of
2158
2088
Hepatocellular
Carcinoma
42500
3500
(Estes et al., 2015)
Cost of liver transplant *
Triple Therapy (SOF +
(Esmat, n.d.)
1226
----PEG-INF/RBV)
Dual Therapy (SOF +
(Esmat, n.d.)
1609
----RBV)
Average cost of Triple
1417.5
and Dual therapy
319.3
---(Abdelsalam, 2015)
SOF + DCV
* This medical care expenses did not include any of treatment regimen for HCV.
Also, it did not include HCV genotyping cost as it was not included as one of the
required investigations in the protocol of HCV management in Egypt.
9. Indirect Burden (DALYs)

The indirect cost were estimated based on calculating disability adjusted life
years (DALYs). DALYs is a metric for measuring the burden of diseases which
introduced for the first time in the Global Burden of Disease study measured the
burden for about 100 diseases in 1990 (Murray & Lopez, 1996). DALYs include
years of life lost to disability (YLDs) and years of life lost due to premature death
(YLLs). Disability weights for calculating YLDs were calculated based on data in
Table IV-8.
Table IV-8 Disability weight of different health states of liver disease(YLDs)
Health State
Disability weight
0
Undiagnosed Chronic Hepatitis cases
Diagnosed Symptomatic Chronic Hepatitis If <30 Y zero, others 0.1
cases
If <30 Y zero, others 0.015
weighted average for Diagnosed
symptomatic Chronic Hepatitis cases
If <30 Y zero, others 0.3
Compensated Cirrhosis
0.4
Esophageal Varices
0.8
Hepatic Encephalopathy
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0.4
0.6

Ascites
HCC
(Estes et al., 2015)

YLLs will be identified by using WHO life expectancy table of Egypt which
show number of years expected to be lived by each age group. The life expectancy in
Egypt has increased in the last 20 years. Life expectancy for male has increased from
63.0 years (IHME, n.d.) in 1990 to 68.3 years (GHO-WHO, 2013) in 2013 while the
female life expectancy has increased from 67.7 years (IHME, n.d.) to 73.6 years
(GHO-WHO, 2013) in the same period. (IHME, n.d.). The life expectancy for
Egyptian population by age group was collected from Global Health Observatory data
repository of WHO then the average of life expectancy of male and female at the
same age group was calculated (Table IV-9).
Table IV-10 Probability of Death from
Background Mortality, Egypt 2013
Age Group Probability of Death
0.000758
1-4 years
0.000478
5-9 years
0.000392
10-14 years
0.000563
15-19 years
0.000835
20-24 years
0.001029
25-29 years
0.001343
30-34 years
0.001597
35-39 years
0.002358
40-44 years
0.004887
45-49 years
0.008921
50-54 years
0.012259
55-59 years
0.019302
60-64 years
0.030268
65-69 years
0.049122
70-74 years
0.07991
75-79 years
0.121357
80-84 years
0.179102
85-89 years
0.244894
90-94 years
0.312166
95-99 years
0.378889
100+ years

Table IV-9 Life expectancy,
Egypt 2013
Age Group Life expectancy
71.65
1-4 years
67.85
5-9 years
63
10-14 years
58.1
15-19 years
53.25
20-24 years
48.5
25-29 years
43.7
30-34 years
39
35-39 years
34.25
40-44 years
29.65
45-49 years
25.25
50-54 years
21.3
55-59 years
17.45
60-64 years
13.95
65-69 years
10.8
70-74 years
8.2
75-79 years
6.1
80-84 years
4.45
85-89 years
3.35
90-94 years
2.65
95-99 years
2.1
100+ years
(GHO-WHO, 2013)
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The monetary value of one DALY was assigned to be $6265 (Estes et al.,
2015). This value was based on calculating the mean value of lost productivity, lost
earning, and the value of a statistical life year (VSLY) by Estes et al., 2015. Also, it
was assumed that there will be 3% annual increase in the value of the DALY between
2015 and 2025.
10. SVR for different treatment regimen

On one hand, SVR 12 for triple therapy (SOF + PEG-INF/RBV) was
estimated to be 90% for 12 weeks treatment course (Doss et al., 2015), while it was
83.3% for the dual therapy (SOF +RBV) for 24 weeks treatment course (Wehmeyer et
al., 2015). We calculated the average of both regimen (86.65%) and use it in our
model to express about the efficacy of HCV treatment protocols in 2015.
On the other hand, SVR 12 for the recent treatment protocol declared by
NCCVH which contains SOF and DCV± RBV was applied in our model from 2016
till 2025. Due to limited literature and small sample size in studies estimating the
efficacy of this protocol on G4, we calculated the average of SVR 12 of this protocol
on available literature for different genotypes which was 95.4% (Asselah, 2014 ;
Degasperi & Aghemo, 2014 ; Nelson et al., 2015 ; Wyles et al., 2015). This calculated
average was almost similar to the one declared by the head of NCCVH about the
efficacy of this new combination which was 95% (Alneweihy, 2015).
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V.

Results
A. Epidemiological Burden of HCV
1. Scenario I:

Under Scenario I, we studied the impact adopting this scenario on the
epidemiological burden of HCV. This scenario represent the current situation where
we used the same treatment rate (about 125,000 patients treated annually), the same
treatment regimen applied by NCCVH in 2015 which composed of the triple and dual
therapy for treating HCV cases (NCCVH, 2015), then the recent treatment protocol
published in December 2015 by NCCVH that depend on SOF and DCV for treating
cases starting from 2016 (Saeed, 2015), the current cost of these treatment regimens,
efficacy of the used drugs, and the current incidence rate. The model calculated the all
HCV viremia cases annually, number of cases under different stages of liver fibrosis
(F0-F3), annual number of liver cirrhosis cases either compensated or decompensated,
hepatocellular carcinoma, and liver related deaths.
The results showed that all HCV viremia cases slightly decreased from 4,664,037
cases by end of 2015 to 4,105,505 cases by 2025 which represent 12% decrease from
the viremia in 2015. The number of compensated cirrhosis cases will increase
gradually to peak in 2019, at 3.8% above the 1,018,515 compensated cirrhosis cases
at 2015, then decline to reach 991,282 cases by 2025 which means 2.7% less than
2015. On the other hand, the decompensated cirrhosis cases decreased by 69.5% from
110,840 patients in 2015 to 33,839 by 2025 (Figure V1).
Figure V1- Number of chronic HCV patients by different disease stages, 2015-2025
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The overall number of cases with cirrhosis (compensated and decompensated) showed
9% decrease in comparison to the number of cases in 2015 to reach 1,025,122 cases
by 2025.
The number of HCC showed gradual increase over the time to reach the peak
26,682 cases by 2023 then slightly decreased to reach 25,544 cases which is 42.3%
higher than the situation at 2015 of 17,953 cases (Figure V3). During this 10 years
period the liver related death was expected to decline by 43.6% according to the
model to reach 25,907 cases by 2025 (Figure V2).
Figure V2- Impact of current
management scenario on the number of
HCC over time

Figure V3- Impact of current
management scenario on Liver Related
deaths over time

2. Scenario II:

During this scenario we estimated the effect of increasing the treatment rate to
treat about 500,000 cases per year starting from 2016 with using the recent treatment
protocol published in December 2015 by NCCVH that depend on SOF and DCV±
RBV (Saeed, 2015).
The results revealed that the total HCV viremia cases will decline by 56.5% from
4,664,037 cases by end of 2015 to 2,027,717 cases by 2025 (Figure V4). The number
of compensated cirrhosis cases will also decreases from 1,018,515 compensated
cirrhosis cases at 2015 to 451,262 cases by 2025 which means 55.7% less than the
cases in 2015, while the decompensated cirrhosis cases decreased by 84.9% from
110,840 patients at 2015 to 16,756 cases by 2025 (Figure V5); and the overall number
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of cases with cirrhosis (compensated and decompensated) showed 58.6% decline
between 2015 and 2025 to reach 468,018 cases by 2025.

Figure V4- Impact of adopting different management scenarios on total number
of HCV viremia cases, 2015-2025

Figure V5- Impact of adopting Scenario II on number of cirrhosis
(compensated and decompensated) cases, 2015-2025

In addition, the number of HCC showed gradual increase over the time by 19.3%
to reach the peak 21,424 cases by 2018, then slightly decreased to become 35.1%
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below the 2015 base of 17,953 cases to reach 11,650 cases by 2025 (Figure V7).
Also, the liver related death was expected to decline by 69.1% from 45.898 deaths to
reach 14,195 cases by 2025 (Figure V6).

Figure V7- Impact of adopting scenario II
on the number of HCC

Figure V6- Impact of adopting scenario II
on the number of liver related deaths

3. Scenario III:

During this scenario we estimated will discuss the effect of treatment about 1
million cases in the coming four years and decrease the incidence rate by 50%
between 2016-2020, then decrease the incidence rate to become 10% of the current
rate. We used the recent treatment protocol published in December 2015 by NCCVH
that depend on SOF and DCV±RBV for treating cases starting from 2016 (Saeed,
2015).
The results revealed dramatic decline in all epidemiological burden indicators
where the total HCV viremia cases showed great decline by 86.3% from 4,664,037
cases by end of 2015 to 636,652 cases by 2025 (Figure V4).The number of
compensated cirrhosis cases will also decreases from 1,018,515 compensated
cirrhosis cases at 2015 to 198,817 cases by 2025 which means 80.5% lower than the
cases in 2015, while the decompensated cirrhosis cases decreased by 92.5% from
110,840 patients at 2015 to 8,314 cases by 2025 (Figure V8); and the overall number
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of cases with cirrhosis (compensated and decompensated) showed 81.7% decline
between 2015 and 2025 to reach 207,130 cases by 2025.
Figure V8- Impact of adopting Scenario III on number of cirrhosis (compensated and
decompensated) cases, 2015-2025

In addition, The implementation of scenario III caused 70.6% decline in HCC
cases from 17,953 cases to reach 5,273 cases by 2025 (Figure V10). Also, the liver
related death was showed more decline where it became 86.6% less during this 10
years period from 45.898 deaths to reach 6,139 cases by 2025 (Figure V9).

Figure V10- Impact of adopting scenario
III on the number of HCC

Figure V9-Impact of adopting scenario
III on the number of liver related deaths
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4. Comparison between the three Scenarios:

By comparing the impact of the three scenarios on the epidemiological burden of
HCV in Egypt between 2015 and 2025, we found that:
 Adoption of Scenario II will drop the total HCV viremia cases by 50.6% fewer
than Scenario I by 2025, while the adoption of Scenario III will go beyond this
level to reach 84.5% lower than Scenario I , where it reaches only 636,652 cases
instead of 4,105,505 patients in Scenario I (Figure V11)
 Implementing Scenario II will result in having 468,018 cirrhosis cases by 2025
incomparable to 1,025,122 cases in Scenario I, a 54.3% decline lower than
Scenario I, while it becomes more lower with Scenario III ,a 79.8% reduction
compared with Scenario I by 2025 (Figure 11)
Figure V11- Impact of adopting different management scenarios on
total viremia and cirrhosis by 2025

 The number of HCC in Scenario II will decrease by 54.4% as compared to
Scenario I to 11,650 cases, and decrease more with adopting Scenario III to
reach 5,273 as compared to 25,544 in Scenario I (Figure V12)
 Also liver related deaths will decrease in Scenario II 45.2% lower than
Scenario I to 12,726 deaths, and decline by 76.3% from Scenario I after
implementing Scenario III to become only 6,139 (Figure V12)
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Figure V12- Impact of adopting different management scenarios on
HCC and liver related deaths by 2025
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B. Economic Burden
1. Scenario I:
It was estimated by the model that the direct costs of management HCV under
Scenario 1 (the current management scenario) would be $2,597,875,687 at 2015 and
decreased gradually to reach $ 1,753,385,280 by 2025 which means that the direct
costs decreased by 32.5% between 2015-2025 (Figure V13). The cumulative direct
cost between 2015-2025 were estimated $23,178,072,617. The DALYs decreased by
78.9%, from 806,756 in 2015 to 170,038 by 2025 (Figure V14), and the cumulative
DALYs were 3,794,828. Based on these DALYs, the indirect cost also decreased
gradually from 5,344,758,798 to 1,126,502,104 by 2025 (Figure V15). The
cumulative indirect cost were calculated $25,140,734,281 from 2015 to 2025. And the
total costs associated with chronic active HCV infection in 2025 ($2,879,887,384)
were 63.7% less than that in 2015 ($7,942,634,484) (Figure V16), where the
cumulative total costs were estimated at $48,318,806,898.

2. Scenario II:
Under Scenario II, the estimated direct costs of management HCV was decreased
53.2% from 2015 value to $ 1,216,061,709 at 2025 (Figure V13). The cumulative
direct cost were estimated $20,478,601,172 between2015-2025. The DALYs
decreased from 806,756 in 2015 to 93,410 by 2025, an 88.4% decline (Figure V14).
Based on these DALYs, the indirect cost also decreased by 2025 to 1,126,502,104 $
618,842,604 (Figure V15). The cumulative DALYs were estimated 3,356,612, and the
cumulative indirect cost were calculated $22,237,554,464 between 2015 and 2025.
And the total costs associated with chronic active HCV infection decreased 76.9%
from2015 value to reach $ 899,324,519 by 2025 (Figure V16). The cumulative total
costs were estimated $42,716,155,636.
3. Scenario III:

Based on Scenario III, the estimated direct costs of management HCV showed
minimal increase in 2016 by 0.2% to reach $2,602,320,222, then it decreased by
53.2% from 2015 value to $ 1,216,061,709 at 2025 (Figure V13). The cumulative
direct cost between 2015-2025 were estimated at $16,202,234,991. The DALYs
decreased from 806,756 in 2015 to 93,410 by 2025, an 88.4% decline (Figure V14),
and the cumulative DALYs were 2,718,098. Based on the DALYs, the indirect cost
also decreased by 2025 to 1,126,502,104 $ 618,842,604 (Figure V15). The cumulative
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indirect cost from 2015 to 2025 were calculated $18,007,401,689. And the total costs
associated with chronic active HCV infection decreased 76.9% from2015 value to
reach $ 899,324,519 by 2025 (Figure V16). The cumulative total costs were estimated
$ 34,209,636,680.
Figure V13- Impact of the different management scenario on the direct cost of
HCV management - Egypt, 2015-2025

Figure V14- Impact of the different management scenario on Disability adjusted
life years due to HCV- Egypt, 2015-2025
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Figure V15- Impact of the different management scenario on the indirect cost of
HCV - Egypt, 2015-2025

Figure V16- Impact of the different management scenario on the total cost of
HCV management- Egypt, 2015-2025

4. Comparison between the three Scenarios:

By comparing the economic burden of HCV when adopting the Scenario II
and Scenario III as compared to the current scenario (Scenario I) in Egypt between
2015 and 2025, we found that:


Adoption of Scenario II will decrease the cumulative DALYs by 11.5%, from
3,794,828 in Scenario I to reach 3,356,612 (Figure V17), which will save
$2,903,179,817 as indirect costs. Also, the cumulative direct costs will
decrease by11.6% s compared with Scenario I to reach $20,478,601,172
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(Figure V18). Hence, the cumulative total cost will decrease as well and save
$5,602,651,262 (Figure V18)


Adoption of Scenario III will decrease the cumulative DALYs by 28.4% from
Scenario I value to become 2,718,098 (Figure V17), which will save
$7,133,332,592 as indirect costs. Also, the cumulative direct costs will
decrease by 30.1% as compared with Scenario I to reach $16,202,234,991
(Figure V18). Hence, the cumulative total cost will decrease as well by 29.2%
and save $14,109,170,218 (Figure V18)
Figure V17- The cumulative Disability Adjusted Life Years of the three
management Scenario of HCV, Egypt 2015-2025

Figure V18- The cumulative direct, indirect and total cost of the three
management scenario of HCV, Egypt 2015-2025
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C. Cost Effectiveness
Cost effectiveness analysis was conducted to identify the most cost effective
scenario. The analysis showed that both of Scenario I and Scenario II were absolute
dominated by Scenario III as both of them have higher cost and higher DALYs (low
effectiveness) than Scenario III. Therefore, Scenario III is the most cost effective
scenario.
Adoption of Scenario III instead of Scenario I between 2015 and 2025 will avert
1,076,729 DALYs, and save $6.97 billion as direct costs and $14.11 billion as total
costs. Therefore, for direct costs, the ICER for Scenario III was -$6,497 for each
DALY averted as compared to Scenario I. In addition, for total costs, the ICER for
Scenario III was -$13,104 for each DALY averted as compared to Scenario I
Adoption of Scenario III instead of Scenario II between 2015 and 2025 will avert
638,514 DALYs, and save $4.28 billion as direct costs and $8.51 billion as total costs.
Therefore, for direct costs, the ICER for Scenario III was -$6,697 for each DALY
averted as compared to Scenario II. In addition, for total costs, the ICER for Scenario
III was -$13,322 for each DALY averted as compared to Scenario II.
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VI.

Discussion and Recommendations:

With the rapid progress in HCV treatment drugs, not only in their efficacy but also
in their prices, in addition to availability of recently published data about the
prevalence of HCV in Egypt, this paper presents an updated figure for the current and
the future burden of this disease from economic and epidemiological prospective. In
addition, it has assessed three different scenarios for management of this huge public
health problem facing our beloved country to enable the policy makers to choose the
most cost effective strategy that is capable of reducing the economic and
epidemiological burden of this disease at the country level.
This paper revealed that the total economic burden of HCV in Egypt according to
the current situation is $7.94 billion which is equivalent to 2.7% of Egypt GDP
(‘Egypt Home’, 2015). The current direct healthcare costs of HCV in Egypt is about
$2.6 billion which consume around 17.4% of the total health expenditure in Egypt
(‘WHO | Hepatitis C’, 2015).
Under the current management strategy, Scenario I, small reduction in the
prevalence of HCV is expected to be achieved after 10 years where it is estimated that
we will have about 4.1 million chronic active HCV patients, 25% of them are in
cirrhotic stage, around 25 thousands suffer from HCC, and expected to still have high
annual number of deaths, about 25 thousands deaths at 2025. In addition, the
economic burden of this strategy is very high where the direct costs are estimated at
$23.3 billion, and the total costs are $48.3 billion between 2015-2025.
Adoption of Scenario II which aims to increase the number of treated patients to
reach half million annually showed significant decrease in all burdens of the disease,
however, adoption of Scenario III which focus aims not only to increase the treatment
rate to reach 1 million patient annually in the coming five years but also adopting
prevention strategy to decrease the annual incidence by 90% in the coming 10 years
will achieve dramatic decrease in the burden of disease. The chronic active HCV
cases are estimated to be about 636 thousands cases with a prevalence rate around
0.7%, and with only $16.2 billion as a direct costs, and total costs $34.2 billion
between 2015-2025 which is 29.2% lower than the cost of Scenario I. Also, it is the
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most cost effective strategy where its adoption will save $13,104 for each DALY
averted as compared to the total costs of Scenario I.
It is highly important for success of this strategy to adopt a comprehensive
approach for dealing with this huge challenge, where the “Plan of Action for the
Prevention, Care and Treatment of Viral Hepatitis, Egypt, 2014-2018” provides the
base for this move. We need to focus on availability and accessibility of the new HCV
treatment drugs to be able to absorb the huge number of patients required to be treated
annually and decrease patients’ waiting list. Also, proper infection control measures,
implementing national standards for blood transfusion and testing, increase public
awareness regarding to mode of transmission and methods of protection are highly
important issues in decreasing the incidence of the disease to ensure proper success of
the strategy. The last thing, which is missing in the Egyptian national plan that needs
a special focus to ensure the success of Scenario III is the screening pillar. It is highly
important to adopt a mass screening policy as it is estimated that the newly diagnosed
HCV patients annually are only 110,000 patients (Razavi et al., 2014). This mass
screening policy is an important tool for success of scenario III to ensure early
detection of patients to provide proper treatment for them and preventing them from
spreading the infection.
In brief, adoption of the current scenario for HCV management will have minimal
effect on decreasing the epidemiological burden of the disease, and have a high direct
and indirect cost. On the other hand, adoption of more rigorous strategy increasing the
treatment rate, screening, and decrease the disease transmission as in Scenario III will
allow dramatic response in the epidemiological burden of the disease and significantly
save direct and indirect costs.
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Annex
The model structure for estimating the economic and epidemiological burden of HCV
in Egypt, 2015-2025
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